Clozapine plasma level monitoring: Current status
Clozapine plasma level monitoring: Current status
复制标题
DOI：
10.1007/bf02326373
复制
发表时间：
1996-12-01
影响因子：
3.5
通讯作者：
Cooper, TB
中科院分区：
文献类型：
--
作者：
Cooper, TB
氯氮平及其代谢物的血药浓度监测可能有助于治疗药物代谢活性异常的患者。对于对这种药物有反应的患者，建议设定一个门槛血浆水平。讨论了性别、年龄、吸烟、其他药物和副作用与血浆氯氮平和代谢物的相互作用。氯氮平和/或代谢物的血药浓度监测建议用于在通常治疗剂量下无反应、在低剂量下出现不良副作用或正在接受其他药物治疗的患者。最后，应该对每天需要600毫克以上的病人进行监测，因为有证据表明，超过这一剂量水平，癫痫发作的发生率会显著增加。有证据表明，高血浆氯氮平水平与癫痫发作有关。
Plasma level monitoring of clozapine and metabolites may prove beneficial in treating patients who show unusual drug metabolic activity. A threshold plasma level for patients who will respond to this medication is suggested. The interaction of gender, age, smoking, other medication and side effects with plasma clozapine and metabolites are discussed. Plasma level monitoring of clozapine and/or metabolites is recommended in patients who do not respond at usual therapeutic dose, who show untoward side effects at low dose or who are treated with other medications. Finally monitoring of patients who require more than 600 mg/day should be implemented because there is evidence that the incidence of seizures increases significantly above this dosage level. There is some evidence that high plasma clozapine levels are associated with seizures.